Cytokinetics maintained at sector perform by RBC

Cytokinetics, Inc. remained at its sector perform, speculative risk, and $8.00 price target by RBC Capital Markets analyst Jason Kantor. The analyst added he believes that CK-'452 will be the major value driver in the long term and that the phase 2 program for CK-'452 in heart failure is robust and well designed, but meaningful efficacy data might not come until year-end 2007. Shares of the South San Francisco, Calif.-based biopharmaceutical company were up 5 cents, or 0.70%, at $7.18. (Nasdaq: CYTK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.